Nuclear Cardiology

Single photon computed tomography (SPECT) and positron emission tomography (PET) molecular imaging are used as primary cardiac imaging modalities to evaluate the function of the heart. It uses radioactive isotopes attached to sugars that are metabolized by cardiomyocytes. This creates an image of the metabolic activity of the heart and shows areas of ischemia or infarct. Other radiotracers can image the heart to diagnosis cardiac amyloidosis and sarcoidosis. 

A study published this week in the Journal of the American College of Cardiology (JACC): Cardiovascular Imaging shows artificial intelligence (AI) algorithms can more rapidly and objectively determine calcium scores in computed tomographic (CT) and positron emission tomographic (PET) images than physicians.[1] The AI also performed well when the images were obtained from very-low-radiation CT attenuation scans. https://doi.org/10.1016/j.jcmg.2022.06.006

Artificial intelligence can objectively determine cardiac calcium scores faster than doctors

A new study shows artificial intelligence (AI) algorithms can more rapidly and objectively determine calcium scores in CT and PET/CT images than physicians.

Comparison of flurpiridaz F-18 PET, SPECT and angiography of the 60-year-old female patients in the Aurora trial. The SPECT scan appeared normal, but flurpiridaz was shown to be more sensitive and showed the ischemia from two blockages in the right coronary artery. The new radiotracer may help expand cardiac PET. #ASNC

Flurpiridaz data shows promise to expand and enhance cardiac PET

The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) PET radiotracer agent.

PET imaging uncovers a surprising new way COVID-19 affects the heart

A new study in JACC: Cardiovascular Imaging focuses on a potential new side effect of COVID-19, highlighting the continued importance of monitoring these patients going forward. 

New PET imager cleared for U.S. sales

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

Big private payer reverses course on cardiac PET/CT coverage

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

U.S. News & World Report children’s hospitals cardiology heart surgery

Lower doses, faster acquisitions: Experts share how to improve PET scans for peds

This week in AJR, experts shared how they were able to reduce FDG PET scan acquisition times by 33%, thus reducing the amount of total radiation exposure to more vulnerable pediatric patients. 

The American Medical Association (AMA) Board of Delegates approved a policy calling on payers to reimburse for the drug regadenoson and not to employ payment policies that push for cardiologists to change the drug they use for pharmacologic stress for one that is considered less safe. The policy was adopted at the AMA 2022 meeting. #AMA #AMA175 #AMAmtg #ASNC

AMA supports reimbursement for pharmacologic stress agent regadenoson

The American Medical Association Board of Delegates approved a policy calling on payers to reimburse for the drug regadenoson and not to employ payment policies that push for cardiologists to change the drug they use for pharmacologic stress for one that is considered less safe.

Researchers have designed a new cardiac SPECT imaging system that could potentially deliver images much faster than current models. The team presented its findings at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), SNMMI 2022.

The need for speed: New-look cardiac SPECT imaging system could be up to 100 times faster than current models

Researchers presented their proposed design of a self-collimating SPECT system at SNMMI 2022.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.